These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21897759)

  • 1. Phosphorus metabolism in chronic kidney disease.
    Fourtounas C
    Hippokratia; 2011 Jan; 15(Suppl 1):50-2. PubMed ID: 21897759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease.
    Goto S; Nakai K; Kono K; Yonekura Y; Ito J; Fujii H; Nishi S
    Clin Exp Nephrol; 2014 Dec; 18(6):925-31. PubMed ID: 24578219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
    Gutiérrez OM
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J; Liu S; Quarles LD
    Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
    Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
    J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What would we like to know, and what do we not know about fibroblast growth factor 23?
    Cozzolino M; Galassi A; Apetrii M; Covic A
    J Nephrol; 2011; 24(6):696-706. PubMed ID: 21786227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD].
    Komaba H
    Clin Calcium; 2010 Jul; 20(7):1028-36. PubMed ID: 20585181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.
    Hasegawa H; Nagano N; Urakawa I; Yamazaki Y; Iijima K; Fujita T; Yamashita T; Fukumoto S; Shimada T
    Kidney Int; 2010 Nov; 78(10):975-80. PubMed ID: 20844473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGF23 in chronic kidney disease.
    Wahl P; Wolf M
    Adv Exp Med Biol; 2012; 728():107-25. PubMed ID: 22396166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
    Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
    Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor 23 and the future of phosphorus management.
    Wolf M
    Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):463-8. PubMed ID: 19770756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF23: its role in renal bone disease.
    Fukagawa M; Kazama JJ
    Pediatr Nephrol; 2006 Dec; 21(12):1802-6. PubMed ID: 16932898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: a case-control study.
    Sliem H; Tawfik G; Moustafa F; Zaki H
    Indian J Endocrinol Metab; 2011 Apr; 15(2):105-9. PubMed ID: 21731867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease.
    Parker VJ; Harjes LM; Dembek K; Young GS; Chew DJ; Toribio RE
    J Vet Intern Med; 2017 May; 31(3):791-798. PubMed ID: 28186657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease.
    Zisman AL; Wolf M
    Curr Opin Nephrol Hypertens; 2010 Jul; 19(4):335-42. PubMed ID: 20583336
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.